Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, Volume Four in the Cancer Sensitizing Agents for Chemotherapy Series focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.

Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing researchBrings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanismsProvides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

1. EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy 2. BCR-ABL inhibitors as sensitizing agents for cancer chemotherapy 3. VEGFR inhibitors as sensitizing agents for cancer chemotherapy 4. ALK inhibitors as sensitizing agents for cancer chemotherapy 5. JAK2 inhibitors as sensitizing agents for cancer chemotherapy 6. FLT3 inhibitors as sensitizing agents for cancer chemotherapy 7. BRAF inhibitors as sensitizing agents for cancer chemotherapy 8. Bruton kinase inhibitors as sensitizing agents for cancer chemotherapy